The Ion Torrent Oncomine Myeloid Research Assay, the first fully-integrated next-generation sequencing platform, will be available in 2020 on the new Ion Torrent Genexus System for research use, according to a press release from Thermo Fisher Scientific. The platform features automated workflow to allow for result delivery within a single day, requiring minimal user intervention and tissue sample input.
The Ion Torrent Oncomine Myeloid Research Assay, the first fully-integrated next-generation sequencing (NGS) platform, will be available in 2020 on the new Ion Torrent Genexus System for research use, according to a press release from Thermo Fisher Scientific. The platform features automated workflow to allow for result delivery within a single day, requiring minimal user intervention and tissue sample input.
The NGS platform was introduced in November 2019 at the Association for Molecular Pathology Annual and was later demonstrated at the 2019 American Society of Hematology (ASH) Annual Meeting and Exposition. The NGS-based platform will both simplify and accelerate the genomic profiling process, which ordinarily can be time-consuming and laborious for clinical researchers.
Only 10 minutes of hands-on time and 2 user touchpoints are required with the Ion Oncomine Myeloid Research Assay for a turnaround time of 1 day. Minimal amounts of the tissue sample are necessary for the system. Because it can also run on small batches of tissue, the system is cost-effective, as well.
"For the past 2 years we have been using Thermo Fisher's NGS technology to analyze myeloid samples, and the Oncomine Myeloid Research Assay provides a comprehensive assessment to identify relevant variants in a single step," Bekim Sadikovic, PhD, associate professor of pathology and laboratory medicine at Western University and division head of the Molecular Diagnostics Division in the Department of Pathology and Laboratory Medicine at London Health Sciences Centre, said in a press release. "Making this assay available on a platform that can deliver results in a single day would provide labs with the answers they need for key mutations such as FLT3-ITDs, TP53, CEBPA, NPM1, KIT, PML-RARA and other biomarkers."
The portfolio of the hematology-oncology research assays has also been expanded to simplify BCR repertoire and rare clone detection, including lymphoid malignancies. The Oncomine BCR IGH-LR Assay will provide researchers with an accurate assessment and somatic hypermutation in samples. This includes cell lines of chronic lymphocytic leukemia and small lymphocytic leukemia. Compared with traditional methods, the presence of rare clones with higher sensitivity and lower limit of detection can be measured with the Oncomine BCR IGH-SR.
The hematology portfolio also includes the Oncomine Childhood Cancer Research Assay. All hematology and oncology assays are compatible with the Ion GeneStudio S5 System in order to streamline NGS workflow for consolidated biomarker testing. The Ion GeneStudio S5 also includes bioinformatics software to provide researchers with more comprehensive information that makes it easier for interpretation.
"The Genexus System holds promise to redefine the genomic profiling paradigm," said Andy Felton, vice president of product management for clinical next-generation sequencing and oncology at Thermo Fisher.
Thermo Fisher Scientific to Bring One-Day Genomic Profiling to Hematology Oncology [news release]. Carlsbad, CA: Thermo Fisher Scientific; December 5, 2019. https://bit.ly/2N7pWcy. Accessed January 7, 2020.